FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044761279> ?p ?o ?g. }

• W2044761279 endingPage "289" @default.
• W2044761279 startingPage "285" @default.
• W2044761279 abstract "Purpose: The combination of radiotherapy and fluorouracil (5-FU) in patients with locally unresectable pancreatic carcinoma has led to a significant increase in survival in comparison with radiotherapy alone. Doxifluridine (5-DFUR) is an orally active fluoropyrimidine, and its cytotoxic metabolite (5-FU) may concentrate in areas of high tumor vascularization. This trial was carried out with the aims of improving locoregional control and making lesions resectable in patients with unresectable pancreatic cancer. Methods: 5-DFUR was given at a dose of 500 mg/m2 b.i.d. by way of mouth for 4 days every other week for a total of four courses, with leucovorin 25 mg b.i.d. orally being given 2 hours before each 5-DFUR administration. External beam RT was administered at a dose of 1000 cGy per week for 3 weeks, followed by a 2-week break and then by 1000 cGy per week for a further 2 weeks (a total dose of 5000 cGy). The patients were restaged 4 weeks after the end of treatment and explored for resection in cases of partial response (PR). Results: A total of 32 patients were treated between 1992 and 1997. Ab initio unresectability was shown by laparotomy (16 cases) or computed tomography (16 cases), and was due to vascular invasion in 27 patients, massive regional nodal metastases in nine, and both in four. The median age was 63 years (range 36–71); performance status (PS) (ECOG): 0–1 = 28 and PS 2 = 4. All the patients had measurable disease and were evaluable for response. There were seven PR (22%), 10 SD (31%), and 15 PD (47%). All of the responders underwent surgical exploration, and radical resection was possible in 5. Three of these patients are still disease-free with a follow-up of 18, 27, and 65 months; the other two cases relapsed 11 and 14 months after surgery. The median survival time was 9 months for the entire group, and 1-year survival rate was 31%. The treatment was never stopped because of toxicity. There were no CTC-NCI grade 3 or 4 toxic events; grade 1–2 diarrhea was observed in 10 cases. Conclusions: This preoperative regimen was feasible and led to a successful surgical resection in 16% of otherwise inoperable cases. The median survival was comparable with the results obtained after 5-FU infusion plus radiotherapy. The resectability rate, and the benefit in terms of survival in the resected patients, make these results worthy of confirmation by larger studies." @default.
• W2044761279 created "2016-06-24" @default.
• W2044761279 creator A5008840195 @default.
• W2044761279 creator A5021938791 @default.
• W2044761279 creator A5034600064 @default.
• W2044761279 creator A5040934952 @default.
• W2044761279 creator A5047999645 @default.
• W2044761279 creator A5060308967 @default.
• W2044761279 creator A5066852333 @default.
• W2044761279 creator A5070704228 @default.
• W2044761279 creator A5072747996 @default.
• W2044761279 date "1999-09-01" @default.
• W2044761279 modified "2023-10-16" @default.
• W2044761279 title "Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service." @default.
• W2044761279 cites W142543190 @default.
• W2044761279 cites W1892409143 @default.
• W2044761279 cites W1922278776 @default.
• W2044761279 cites W1930757563 @default.
• W2044761279 cites W1968793335 @default.
• W2044761279 cites W1969597064 @default.
• W2044761279 cites W1976128207 @default.
• W2044761279 cites W1983513991 @default.
• W2044761279 cites W2040693082 @default.
• W2044761279 cites W2072671145 @default.
• W2044761279 cites W2093791334 @default.
• W2044761279 cites W2094724267 @default.
• W2044761279 cites W2131728068 @default.
• W2044761279 cites W2141387649 @default.
• W2044761279 cites W2145756962 @default.
• W2044761279 cites W2167805334 @default.
• W2044761279 cites W2240373795 @default.
• W2044761279 cites W2470353582 @default.
• W2044761279 cites W4231031590 @default.
• W2044761279 cites W4253769310 @default.
• W2044761279 cites W4293241248 @default.
• W2044761279 doi "https://doi.org/10.1016/s0360-3016(99)00205-9" @default.
• W2044761279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10487547" @default.
• W2044761279 hasPublicationYear "1999" @default.
• W2044761279 type Work @default.
• W2044761279 sameAs 2044761279 @default.
• W2044761279 citedByCount "58" @default.
• W2044761279 countsByYear W20447612792012 @default.
• W2044761279 countsByYear W20447612792013 @default.
• W2044761279 countsByYear W20447612792014 @default.
• W2044761279 countsByYear W20447612792015 @default.
• W2044761279 countsByYear W20447612792023 @default.
• W2044761279 crossrefType "journal-article" @default.
• W2044761279 hasAuthorship W2044761279A5008840195 @default.
• W2044761279 hasAuthorship W2044761279A5021938791 @default.
• W2044761279 hasAuthorship W2044761279A5034600064 @default.
• W2044761279 hasAuthorship W2044761279A5040934952 @default.
• W2044761279 hasAuthorship W2044761279A5047999645 @default.
• W2044761279 hasAuthorship W2044761279A5060308967 @default.
• W2044761279 hasAuthorship W2044761279A5066852333 @default.
• W2044761279 hasAuthorship W2044761279A5070704228 @default.
• W2044761279 hasAuthorship W2044761279A5072747996 @default.
• W2044761279 hasConcept C121608353 @default.
• W2044761279 hasConcept C126322002 @default.
• W2044761279 hasConcept C126838900 @default.
• W2044761279 hasConcept C141071460 @default.
• W2044761279 hasConcept C143998085 @default.
• W2044761279 hasConcept C2778424827 @default.
• W2044761279 hasConcept C2780210213 @default.
• W2044761279 hasConcept C2780456651 @default.
• W2044761279 hasConcept C509974204 @default.
• W2044761279 hasConcept C71924100 @default.
• W2044761279 hasConceptScore W2044761279C121608353 @default.
• W2044761279 hasConceptScore W2044761279C126322002 @default.
• W2044761279 hasConceptScore W2044761279C126838900 @default.
• W2044761279 hasConceptScore W2044761279C141071460 @default.
• W2044761279 hasConceptScore W2044761279C143998085 @default.
• W2044761279 hasConceptScore W2044761279C2778424827 @default.
• W2044761279 hasConceptScore W2044761279C2780210213 @default.
• W2044761279 hasConceptScore W2044761279C2780456651 @default.
• W2044761279 hasConceptScore W2044761279C509974204 @default.
• W2044761279 hasConceptScore W2044761279C71924100 @default.
• W2044761279 hasIssue "2" @default.
• W2044761279 hasLocation W20447612791 @default.
• W2044761279 hasLocation W20447612792 @default.
• W2044761279 hasOpenAccess W2044761279 @default.
• W2044761279 hasPrimaryLocation W20447612791 @default.
• W2044761279 hasRelatedWork W1971164957 @default.
• W2044761279 hasRelatedWork W1975840453 @default.
• W2044761279 hasRelatedWork W2110125130 @default.
• W2044761279 hasRelatedWork W2130974107 @default.
• W2044761279 hasRelatedWork W2224073645 @default.
• W2044761279 hasRelatedWork W2348325681 @default.
• W2044761279 hasRelatedWork W2357291728 @default.
• W2044761279 hasRelatedWork W2439317909 @default.
• W2044761279 hasRelatedWork W2474665074 @default.
• W2044761279 hasRelatedWork W4245694863 @default.
• W2044761279 hasVolume "45" @default.
• W2044761279 isParatext "false" @default.
• W2044761279 isRetracted "false" @default.
• W2044761279 magId "2044761279" @default.
• W2044761279 workType "article" @default.